Loading...
OTCM
THMO
Market cap0kUSD
Sep 24, Last price  
0.00USD
Name

Cesca Therapeutics Inc

Chart & performance

D1W1MN
OTCM:THMO chart
P/E
—
P/S
0.00
EPS
—
Div yield, %
—
Shrs. gr., 5y
125.20%
Rev. gr., 5y
-0.47%
Revenues
9m
-9.90%
10,177,00012,048,00016,751,00021,946,00019,799,00023,088,00023,400,00019,023,00017,963,00015,987,00016,042,00011,929,00014,525,00012,026,0009,672,00013,047,0009,744,0009,294,00010,483,0009,445,000
Net income
-18m
L+59.49%
-8,220,000-6,142,000-6,776,000-9,181,000-8,550,000-5,193,000-2,567,000-4,986,000-3,086,000-8,631,000-14,852,000-18,588,000-29,095,000-4,566,000-39,716,000-9,497,000-16,351,000-11,379,000-11,270,000-17,975,000
CFO
-4m
L-48.91%
-7,931,000-2,998,000-7,762,000-8,451,000-8,796,000-4,428,000-2,092,000-3,885,000-3,082,000-7,836,000-10,649,000-9,625,000-7,215,000-3,317,000-6,983,000-3,260,000-14,393,000-6,620,000-7,283,000-3,721,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

ThermoGenesis Holdings, Inc., founded in 1986 and based in Rancho Cordova, California, is a global innovator specializing in automated systems for cell-banking, cell-processing, and cell-based therapeutic applications. The company's advanced solutions are available across the United States, China, the United Arab Emirates, Vietnam, and other international regions. Its product portfolio encompasses medical devices crucial for automated cell processing. For clinical bio-banking purposes, ThermoGenesis provides the AXP II Automated Cell Separation System, a fully closed system designed for isolating stem and progenitor cells from umbilical cord blood. Complementing this is the BioArchive Automated Cryopreservation System, a robotic, liquid nitrogen-controlled system for both freezing and long-term cryogenic storage of cord blood samples and cell therapeutic products used in clinical environments. In the realm of point-of-care applications, the company offers the XP Point-of-Care System, an automated, sterile, and closed platform that facilitates the rapid processing of autologous stem cells derived from peripheral blood or bone marrow aspirate directly within clinical settings such as surgical centers. Additionally, the PXP-1000 System is another automated, closed solution, engineered for fast and reproducible separation of multiple cellular components from blood with minimal red blood cell contamination. For general laboratory use, ThermoGenesis provides its X-Series cell processing products, including X-Lab for cell isolation, the X-Wash System for efficient cell washing and reformulation, and X-Mini for high-efficiency, small-scale cell purification. Beyond its product offerings, the company also delivers contract development and manufacturing (CDMO) services specifically for cell and cell-based gene therapies. Its medical device products are marketed and sold through a network of independent distributors, as well as directly to end-user customers. The company, formerly known as Cesca Therapeutics Inc., officially adopted the name ThermoGenesis Holdings, Inc. in November 2019.

Key people

Xiaochun Xu
Chairman of the Board, President, Chief Executive Officer · since 2017
Venkatesh Ponemone
Executive Director of India Operations, Director of Clinical and Scientific Affairs
Jeffery Cauble
Principal Financial Officer, Principal Accounting Officer · since 2017
Kimberly Kay Ellner
Vice President of Manufacturing and Global Supply Chain · since 2016
Russell M. Medford
Director · since 2017
Joseph Thomis
Director · since 2017
James Xu
Director · since 2016
Debra Donaghy
Independent Director · since 2019
Mahendra S. Rao
Independent Director · since 2014
Denis Michael Rhein
Independent Director · since 2014
IPO date
Jun 05, 1987
Employees
40
Domiciled in
US
Incorporated in
US
Legal address
C/O The Company Corporation
251 LITTLE FALLS DRIVE
Wilmington, DE 19808
US
Headquarters
2711 Citrus Road
Rancho Cordova, CA 95742
US
Previous name
Cesca Therapeutics Inc.

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT